Argenx Se (ARGX) Income towards Parent Company (2016 - 2026)
Argenx Se (ARGX) posted quarterly Income towards Parent Company of $472.0 million for Q2 2026, up 92.37% year-on-year from $245.4 million in Q2 2025, and up 28.96% on a QoQ basis from $366.0 million in Q1 2026.
Argenx Se (ARGX) Income towards Parent Company (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Income towards Parent Company for 11 consecutive years, with $472.0 million the latest figure, recorded in Q2 2026.
- Quarterly Income towards Parent Company rose 92.37% year-over-year to $472.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.7 billion (up 34.01% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
- Income towards Parent Company rose to $472.0 million in Q2 2026 per ARGX's latest filing, from $366.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for ARGX reached as high as $774.2 million in Q4 2024 and fell as low as -$227.2 million in Q1 2022.
- A 5-year average of $186.5 million and a median of $130.2 million in 2024 frame the typical range for Income towards Parent Company.
- The largest YoY upside for Income towards Parent Company was 2816.87% in 2022 against a maximum downside of 661.88% in 2022.
- Year by year, Income towards Parent Company stood at -$38.6 million in 2022, then sank by 156.84% to -$99.2 million in 2023, then soared by 880.62% to $774.2 million in 2024, then slumped by 31.16% to $532.9 million in 2025, then retreated by 11.44% to $472.0 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $472.0 million, $366.0 million, and $532.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 472.00 Mn |
| Mar 31, 2026 | 366.00 Mn |
| Dec 31, 2025 | 532.95 Mn |
| Sep 30, 2025 | 344.26 Mn |
| Jun 30, 2025 | 245.36 Mn |
| Mar 31, 2025 | 169.00 Mn |
| Dec 31, 2024 | 774.16 Mn |
| Sep 30, 2024 | 91.41 Mn |
| Jun 30, 2024 | 29.07 Mn |
| Mar 31, 2024 | -61.60 Mn |
| Dec 31, 2023 | -99.17 Mn |
| Sep 30, 2023 | -72.64 Mn |
| Jun 30, 2023 | -94.37 Mn |
| Mar 31, 2023 | 28.87 Mn |
| Dec 31, 2022 | -38.61 Mn |
| Sep 30, 2022 | 235.04 Mn |
| Jun 30, 2022 | 663.12 Mn |
| Mar 31, 2022 | -227.19 Mn |
| Dec 31, 2021 | -237.82 Mn |
| Sep 30, 2021 | -233.61 Mn |